{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T03:46:19Z","timestamp":1791171979258,"version":"4.1.0"},"reference-count":81,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"GlaxoSmithKline, Collegeville, PA"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The mechanism of idiopathic (autoimmune) thrombocytopenic purpura (ITP) has historically been attributed to platelet autoantibody production and the resultant platelet destruction. More recent evidence suggests a multifactorial pathogenesis. A complex picture of the immune processes involved in autoimmunity has emerged over the last decade with the identification and characterization of immunoregulatory elements (receptors, cytokines, and other signaling molecules) and cell trafficking patterns. An understanding of the interplay of cellular and humoral immune responses in the breakdown of self-tolerance has brought to light unrecognized mechanisms of the autoimmune destruction of platelets in ITP and potential targets for future therapeutic advances. The failure of the bone marrow to maximally increase platelet production also appears to play an important role in the thrombocytopenia of ITP. Treatment strategies targeting the thrombopoietin receptor to increase platelet production are a promising new approach to the management of ITP.<\/jats:p>","DOI":"10.1634\/theoncologist.2008-0132","type":"journal-article","created":{"date-parts":[[2009,1,14]],"date-time":"2009-01-14T22:34:50Z","timestamp":1231972490000},"page":"12-21","source":"Crossref","is-referenced-by-count":69,"title":["Chronic Idiopathic Thrombocytopenic Purpura: Mechanisms of Pathogenesis"],"prefix":"10.1093","volume":"14","author":[{"given":"Terry","family":"Gernsheimer","sequence":"first","affiliation":[{"name":"University of Washington Medical School\u2013Seattle, Puget Sound Blood Center, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2009,1,14]]},"reference":[{"key":"2021122207535953400_R1","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1056\/NEJMra010501","article-title":"Immune thrombocytopenic purpura","volume":"346","author":"Cines","year":"2002","journal-title":"N Engl J Med"},{"key":"2021122207535953400_R2","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1053\/tmrv.2003.50004","article-title":"Cellular immune mechanisms in autoimmune thrombocytopenic purpura: An update","volume":"17","author":"Coopamah","year":"2003","journal-title":"Transfus Med Rev"},{"key":"2021122207535953400_R3","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1532\/IJH97.04176","article-title":"The role of autoreactive T-cells in the pathogenesis of idiopathic thrombocytopenic purpura","volume":"81","author":"Kuwana","year":"2005","journal-title":"Int J Hematol"},{"key":"2021122207535953400_R4","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1182\/blood.V67.1.86.86","article-title":"Platelet turnover and kinetics in immune thrombocytopenic purpura: Results with autologous 111In-labeled platelets and homologous 51Cr-labeled platelets differ","volume":"67","author":"Heyns","year":"1986","journal-title":"Blood"},{"key":"2021122207535953400_R5","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1365-2141.1974.tb06780.x","article-title":"Platelet survival and platelet production in idiopathic thrombocytopenic purpura (ITP)","volume":"27","author":"Braneh\u00f6g","year":"1974","journal-title":"Br J Haematol"},{"key":"2021122207535953400_R6","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1056\/NEJM198904133201505","article-title":"Mechanisms of response to treatment in autoimmune thrombocytopenic purpura","volume":"320","author":"Gernsheimer","year":"1989","journal-title":"N Engl J Med"},{"key":"2021122207535953400_R7","first-page":"1","article-title":"Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura","volume":"38","author":"Harrington","year":"1951","journal-title":"J Lab Clin Med"},{"key":"2021122207535953400_R8","doi-asserted-by":"crossref","first-page":"433","DOI":"10.7326\/0003-4819-38-3-433","article-title":"Immunologic mechanisms in idiopathic and neonatal thrombocytopenic purpura","volume":"38","author":"Harrington","year":"1953","journal-title":"Ann Intern Med"},{"key":"2021122207535953400_R9","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1046\/j.1365-2141.1996.d01-1967.x","article-title":"Oligoclonal accumulation of T cells in peripheral blood from patients with idiopathic thrombocytopenic purpura","volume":"95","author":"Shimomura","year":"1996","journal-title":"Br J Haematol"},{"key":"2021122207535953400_R10","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0037-1963(00)90102-1","article-title":"Autoantibodies and autoantigens in chronic immune thrombocytopenic purpura","volume":"37","author":"McMillan","year":"2000","journal-title":"Semin Hematol"},{"key":"2021122207535953400_R11","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1046\/j.1365-2141.1998.00828.x","article-title":"Recombinant human natural autoantibodies against GPIIb\/IIIa inhibit binding of autoantibodies from patients with AITP","volume":"102","author":"Escher","year":"1998","journal-title":"Br J Haematol"},{"key":"2021122207535953400_R12","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1182\/blood.V80.6.1386.1386","article-title":"The molecular immunology of human platelet proteins","volume":"80","author":"Kunicki","year":"1992","journal-title":"Blood"},{"key":"2021122207535953400_R13","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1182\/blood.V83.4.1024.1024","article-title":"Spectrum of Ig classes, specificities, and titers of serum antiglycoproteins in chronic idiopathic thrombocytopenic purpura","volume":"83","author":"He","year":"1994","journal-title":"Blood"},{"key":"2021122207535953400_R14","first-page":"629","article-title":"Platelet destruction in autoimmune thrombocytopenic purpura: Kinetics and clearance of indium-111-labeled autologous platelets","volume":"30","author":"Stratton","year":"1989","journal-title":"J Nucl Med"},{"key":"2021122207535953400_R15","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/ajh.20408","article-title":"Thrombocytopenic conditions\u2014autoimmunity and hypercoagulability: Commonalities and differences in ITP, TTP, HIT, and APS","volume":"80","author":"Kravitz","year":"2005","journal-title":"Am J Hematol"},{"key":"2021122207535953400_R16","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1182\/blood.V100.4.1388.h81602001388_1388_1398","article-title":"Genetic analysis of autoantibodies in idiopathic thrombocytopenic purpura reveals evidence of clonal expansion and somatic mutation","volume":"100","author":"Roark","year":"2002","journal-title":"Blood"},{"key":"2021122207535953400_R17","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/s002770050173","article-title":"Platelet autoantibodies (IgG, IgM, IgA) against glycoproteins IIb\/IIIa and Ib\/IX in patients with thrombocytopenia","volume":"72","author":"Kiefel","year":"1996","journal-title":"Ann Hematol"},{"key":"2021122207535953400_R18","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1182\/blood.V70.4.1040.1040","article-title":"Platelet-associated and plasma anti-glycoprotein autoantibodies in chronic ITP","volume":"70","author":"McMillan","year":"1987","journal-title":"Blood"},{"key":"2021122207535953400_R19","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood.V59.1.23.23","article-title":"Specificity of autoantibodies in autoimmune thrombocytopenia","volume":"59","author":"van Leeuwen","year":"1982","journal-title":"Blood"},{"key":"2021122207535953400_R20","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1182\/blood.V60.4.1050.1050","article-title":"A prospective study of the usefulness of the measurement of platelet-associated IgG for the diagnosis of idiopathic thrombocytopenic purpura","volume":"60","author":"Kelton","year":"1982","journal-title":"Blood"},{"key":"2021122207535953400_R21","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.1182\/blood-2003-09-3352","article-title":"Platelet-associated autoantibodies as detected by a solid-phase modified antigen capture ELISA test (MACE) are a useful prognostic factor in idiopathic thrombocytopenic purpura","volume":"103","author":"Fabris","year":"2004","journal-title":"Blood"},{"key":"2021122207535953400_R22","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1182\/blood.V87.10.4245.bloodjournal87104245","article-title":"Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura: Relationship to platelet phenotype and antiplatelet T-cell reactivity","volume":"87","author":"Semple","year":"1996","journal-title":"Blood"},{"key":"2021122207535953400_R23","first-page":"914","article-title":"Type 1 and type 2 T-cell profiles in idiopathic thrombocytopenic purpura","volume":"90","author":"Wang","year":"2005","journal-title":"Haematologica"},{"key":"2021122207535953400_R24","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/nm921","article-title":"T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura","volume":"9","author":"Olsson","year":"2003","journal-title":"Nat Med"},{"key":"2021122207535953400_R25","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s002770000177","article-title":"A transforming growth factor-beta1-mediated bystander immune suppression could be associated with remission of chronic idiopathic thrombocytopenic purpura","volume":"79","author":"Andersson","year":"2000","journal-title":"Ann Hematol"},{"key":"2021122207535953400_R26","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1600-0609.2005.00622.x","article-title":"Cell-mediated lysis of autologous platelets in chronic idiopathic thrombocytopenic purpura","volume":"76","author":"Zhang","year":"2006","journal-title":"Eur J Haematol"},{"key":"2021122207535953400_R27","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1054\/blre.2001.0171","article-title":"Pathophysiology and thrombokinetics in autoimmune thrombocytopenia","volume":"16","author":"Gernsheimer","year":"2002","journal-title":"Blood Rev"},{"key":"2021122207535953400_R28","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/j.1365-2141.2007.06737.x","article-title":"CD8+ T cells suppress autologous megakaryocyte apoptosis in idiopathic thrombocytopenic purpura","volume":"139","author":"Li","year":"2007","journal-title":"Br J Haematol"},{"key":"2021122207535953400_R29","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1182\/blood.V82.5.1538.1538","article-title":"Severe chronic autoimmune thrombocytopenic purpura is associated with an expansion of CD56+ CD3- natural killer cells subset","volume":"82","author":"Garcia-Suarez","year":"1993","journal-title":"Blood"},{"issue":"suppl 1","key":"2021122207535953400_R30","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/stem.5530140711","article-title":"The physiology of platelet production","volume":"14","author":"Kuter","year":"1996","journal-title":"Stem Cells"},{"key":"2021122207535953400_R31","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1172\/JCI106077","article-title":"Thrombokinetics in man","volume":"48","author":"Harker","year":"1969","journal-title":"J Clin Invest"},{"key":"2021122207535953400_R32","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1172\/JCI113060","article-title":"Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura: Evidence of both impaired platelet production and increased platelet clearance","volume":"80","author":"Ballem","year":"1987","journal-title":"J Clin Invest"},{"key":"2021122207535953400_R33","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1182\/blood.V65.3.584.584","article-title":"Platelet kinetics in patients with idiopathic thrombocytopenic purpura and moderate thrombocytopenia","volume":"65","author":"Stoll","year":"1985","journal-title":"Blood"},{"key":"2021122207535953400_R34","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/BF01733073","article-title":"Platelet survival determined with 51Cr versus 111In","volume":"63","author":"Kiefel","year":"1985","journal-title":"Klin Wochenschr"},{"key":"2021122207535953400_R35","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1532\/IJH97.04168","article-title":"The effect of antiplatelet autoantibodies on megakaryocytopoiesis","volume":"81","author":"McMillan","year":"2005","journal-title":"Int J Hematol"},{"key":"2021122207535953400_R36","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1001\/jama.239.23.2460","article-title":"Antibody against megakaryocytes in idiopathic thrombocytopenic purpura","volume":"239","author":"McMillan","year":"1978","journal-title":"JAMA"},{"key":"2021122207535953400_R37","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1182\/blood-2003-01-0275","article-title":"Ultrastructural study shows morphologic features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura","volume":"103","author":"Houwerzijl","year":"2004","journal-title":"Blood"},{"key":"2021122207535953400_R38","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1182\/blood-2002-05-1475","article-title":"Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro","volume":"102","author":"Chang","year":"2003","journal-title":"Blood"},{"key":"2021122207535953400_R39","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1055\/s-0038-1650641","article-title":"Serum thrombopoietin (TPO) levels in patients with amegakaryocytic thrombocytopenia are much higher than those with immune thrombocytopenic purpura","volume":"76","author":"Mukai","year":"1996","journal-title":"Thromb Haemost"},{"key":"2021122207535953400_R40","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1172\/JCI26674","article-title":"The molecular mechanisms that control thrombopoiesis","volume":"115","author":"Kaushansky","year":"2005","journal-title":"J Clin Invest"},{"key":"2021122207535953400_R41","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S1359-6101(01)00030-2","article-title":"Thrombopoietin: A pan-hematopoietic cytokine","volume":"13","author":"Geddis","year":"2002","journal-title":"Cytokine Growth Factor Rev"},{"key":"2021122207535953400_R42","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1182\/blood.V86.2.540.bloodjournal862540","article-title":"Purification and biologic characterization of plasma-derived megakaryocyte growth and development factor","volume":"86","author":"Hunt","year":"1995","journal-title":"Blood"},{"key":"2021122207535953400_R43","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/0092-8674(94)90450-2","article-title":"Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl","volume":"77","author":"Bartley","year":"1994","journal-title":"Cell"},{"key":"2021122207535953400_R44","doi-asserted-by":"crossref","first-page":"4054","DOI":"10.1182\/blood.V86.11.4054.bloodjournal86114054","article-title":"Regulation of platelet activation in vitro by the c-Mpl ligand, thrombopoietin","volume":"86","author":"Chen","year":"1995","journal-title":"Blood"},{"key":"2021122207535953400_R45","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1182\/blood.V87.11.4664.bloodjournal87114664","article-title":"Thrombopoietin primes human platelet aggregation induced by shear stress and by multiple agonists","volume":"87","author":"Oda","year":"1996","journal-title":"Blood"},{"key":"2021122207535953400_R46","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1046\/j.1365-2141.2003.04292.x","article-title":"Thrombopoietin increases platelet adhesion under flow and decreases rolling","volume":"121","author":"Van Os","year":"2003","journal-title":"Br J Haematol"},{"key":"2021122207535953400_R47","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1182\/blood.V85.10.2720.bloodjournal85102720","article-title":"The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit","volume":"85","author":"Kuter","year":"1995","journal-title":"Blood"},{"key":"2021122207535953400_R48","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1046\/j.1365-2141.1999.01571.x","article-title":"Interaction of thrombopoietin with the platelet c-mpl receptor in plasma: Binding, internalization, stability and pharmacokinetics","volume":"106","author":"Li","year":"1999","journal-title":"Br J Haematol"},{"key":"2021122207535953400_R49","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1046\/j.1365-2141.1997.3823196.x","article-title":"Thrombopoietin levels in patients with primary and reactive thrombocytosis","volume":"99","author":"Cerutti","year":"1997","journal-title":"Br J Haematol"},{"key":"2021122207535953400_R50","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1046\/j.1365-2141.1996.d01-1702.x","article-title":"Circulating thrombopoietin level in chronic immune thrombocytopenic purpura","volume":"93","author":"Kosugi","year":"1996","journal-title":"Br J Haematol"},{"key":"2021122207535953400_R51","doi-asserted-by":"crossref","first-page":"4068","DOI":"10.1182\/blood.V87.10.4068.bloodjournal87104068","article-title":"Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction","volume":"87","author":"Emmons","year":"1996","journal-title":"Blood"},{"key":"2021122207535953400_R52","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/ajh.20104","article-title":"Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodies","volume":"76","author":"Aledort","year":"2004","journal-title":"Am J Hematol"},{"key":"2021122207535953400_R53","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1055\/s-0038-1650545","article-title":"Regulation of serum thrombopoietin levels by platelets and megakaryocytes in patients with aplastic anaemia and idiopathic thrombocytopenic purpura","volume":"76","author":"Ichikawa","year":"1996","journal-title":"Thromb Haemost"},{"key":"2021122207535953400_R54","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1182\/blood.V108.11.1075.1075","article-title":"The effect of tumor necrosis factor (TNF\u03b1) inhibition on platelet counts in adults and children with persistent ITP","volume":"108","author":"Tarantino","year":"2006","journal-title":"Blood"},{"key":"2021122207535953400_R55","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1182\/blood-2003-12-4126","article-title":"Anti-CD40L: Biology and therapy in ITP","volume":"103","author":"Schwartz","year":"2004","journal-title":"Blood"},{"key":"2021122207535953400_R56","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/j.1745-7254.2005.00088.x","article-title":"Mycophenolate mofetil as a treatment for refractory idiopathic thrombocytopenia purpura","volume":"26","author":"Zhang","year":"2005","journal-title":"Acta Pharmacol Sin"},{"key":"2021122207535953400_R57","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1182\/blood.V88.9.3354.bloodjournal8893354","article-title":"Differential mechanisms in the regulation of endogenous levels of thrombopoietin and interleukin-11 during thrombocytopenia: Insight into the regulation of platelet production","volume":"88","author":"Chang","year":"1996","journal-title":"Blood"},{"key":"2021122207535953400_R58","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1182\/blood.V104.11.511.511","article-title":"A phase 2 placebo controlled study evaluating the platelet response and safety of weekly dosing with a novel t thrombopoietic protein (AMG531) in thrombocytopenic patients with immune thrombocytopenic purpura (ITP)","volume":"104","author":"Kuter","year":"2004","journal-title":"Blood"},{"key":"2021122207535953400_R59","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.exphem.2004.09.006","article-title":"Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist","volume":"33","author":"Erickson-Miller","year":"2005","journal-title":"Exp Hematol"},{"key":"2021122207535953400_R60","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1056\/NEJMoa073275","article-title":"Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura","volume":"357","author":"Bussel","year":"2007","journal-title":"N Engl J Med"},{"key":"2021122207535953400_R61","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1200\/JCO.2000.18.15.2852","article-title":"Enhancement of platelet recovery after myelosuppressive chemotherapy by recombinant megakaryocyte growth and development factor in patients with advanced cancer","volume":"18","author":"Basser","year":"2000","journal-title":"J Clin Oncol"},{"key":"2021122207535953400_R62","doi-asserted-by":"crossref","first-page":"364","DOI":"10.7326\/0003-4819-132-5-200003070-00005","article-title":"Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer","volume":"132","author":"Vadhan-Raj","year":"2000","journal-title":"Ann Intern Med"},{"key":"2021122207535953400_R63","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1182\/blood.V99.7.2599","article-title":"Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor","volume":"99","author":"Basser","year":"2002","journal-title":"Blood"},{"key":"2021122207535953400_R64","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0140-6736(08)60203-2","article-title":"Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: A double-blind randomised controlled trial","volume":"371","author":"Kuter","year":"2008","journal-title":"Lancet"},{"key":"2021122207535953400_R65","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1182\/blood.V108.11.477.477","article-title":"Single and multiple oral doses of AKR-501 (YM477) increase the platelet count in healthy volunteers","volume":"108","author":"Desjardins","year":"2006","journal-title":"Blood"},{"key":"2021122207535953400_R66","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1056\/NEJMoa054626","article-title":"AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP","volume":"355","author":"Bussel","year":"2006","journal-title":"N Engl J Med"},{"key":"2021122207535953400_R67","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1182\/blood.V110.11.565.565","article-title":"Evaluation of AMG 531 efficacy in nonsplenectomized patients with chronic immune thrombocytopenic purpura (ITP) in a randomized placebo-controlled phase 3 study","volume":"110","author":"Kuter","year":"2007","journal-title":"Blood"},{"key":"2021122207535953400_R68","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1182\/blood.V110.11.2.2","article-title":"Evaluation of AMG 531 efficacy in splenectomized patients with chronic immune thrombocytopenic purpura (ITP) in a randomized placebo-controlled phase 3 study","volume":"110","author":"Gernsheimer","year":"2007","journal-title":"Blood"},{"key":"2021122207535953400_R69","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1182\/blood.V110.11.568.568","article-title":"Long-term dosing of AMG 531 in thrombocytopenic patients with immune thrombocytopenic purpura: 2-year update","volume":"110","author":"Bussel","year":"2007","journal-title":"Blood"},{"key":"2021122207535953400_R70","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1182\/blood.V110.11.1300.1300","article-title":"Evaluation of AMG 531 safety in splenectomized (S) and nonsplenectomized (NS) patients with chronic immune thrombocytopenic purpura (ITP) in two randomized placebo-controlled phase 3 studies","volume":"110","author":"Lyons","year":"2007","journal-title":"Blood"},{"key":"2021122207535953400_R71","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1182\/blood.V104.11.2910.2910","article-title":"Discovery of SB-497115, a small-molecule thrombopoietin (TPO) receptor agonist for the treatment of thrombocytopenia","volume":"104","author":"Luengo","year":"2004","journal-title":"Blood"},{"issue":"suppl 1","key":"2021122207535953400_R72","first-page":"143","article-title":"Eltrombopag raises platelet count and reduces bleeding compared with placebo during short-term treatment in chronic idiopathic thrombocytopenic purpura: A phase III study","volume":"92","author":"Bussel","year":"2007","journal-title":"Haematologica"},{"key":"2021122207535953400_R73","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1182\/blood.V110.11.566.566","article-title":"Long-term safety and efficacy of oral eltrombopag for the treatment of subjects with idiopathic thrombocytopenic purpura (ITP): Preliminary data from the EXTEND study","volume":"110","author":"Bussel","year":"2007","journal-title":"Blood"},{"key":"2021122207535953400_R74","doi-asserted-by":"crossref","first-page":"4739","DOI":"10.1182\/blood-2006-11-057968","article-title":"Phase 1 clinical study of eltrom-bopag, an oral, nonpeptide thrombopoietin receptor agonist","volume":"109","author":"Jenkins","year":"2007","journal-title":"Blood"},{"key":"2021122207535953400_R75","volume-title":"Promacta (Eltrombopag Tablets). FDA Oncologic Drug Advisory Committee Briefing Document","author":"U.S. Food and Drug Administration"},{"key":"2021122207535953400_R76","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1182\/blood.V110.11.1299.1299","article-title":"Safety of eltrombopag, an oral non-peptide platelet growth factor, in the treatment of thrombocytopenia: Results of four randomized, placebo-controlled studies","volume":"110","author":"Bussel","year":"2007","journal-title":"Blood"},{"key":"2021122207535953400_R77","volume-title":"Nplate [package insert]","year":"2008"},{"key":"2021122207535953400_R78","volume-title":"Background Information for the Oncologic Drug Advisory Committee (ODAC) Meeting 12 March 2008","author":"U.S. Food and Drug Administration"},{"issue":"suppl 1","key":"2021122207535953400_R79","first-page":"125","article-title":"Risk of thromboembolic events among patients with chronic idiopathic thrombocytopenic purpura (ITP)","volume":"93","author":"Bennett","year":"2008","journal-title":"Haematologica"},{"key":"2021122207535953400_R80","doi-asserted-by":"crossref","first-page":"162","DOI":"10.2174\/157016307782109698","article-title":"Biologic aspects of thrombopoietin and the development of novel thrombopoietic agents for clinical use","volume":"4","author":"Evangelista","year":"2007","journal-title":"Curr Drug Discov Technol"},{"key":"2021122207535953400_R81","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1182\/blood.V110.11.1298.1298","article-title":"Single and multiple oral doses of LGD-4665, a small molecule thrombopoietin receptor agonist, increase platelet counts in healthy male subjects","volume":"110","author":"Dziewanowska","year":"2007","journal-title":"Blood"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2008-0132","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2008-0132","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/14\/1\/12\/41841920\/oncolo_14_1_12.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/14\/1\/12\/41841920\/oncolo_14_1_12.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T07:17:38Z","timestamp":1640157458000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/14\/1\/12\/6397484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1,1]]},"references-count":81,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2009,1,14]]},"published-print":{"date-parts":[[2009,1,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2008-0132","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2009,1,1]]},"published":{"date-parts":[[2009,1,1]]}}}